About Fabhalta® (iptacopan) Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway 6-7.

For both induction and maintenance therapy, subcutaneous guselkumab significantly improves clinical outcomes in patients with ...

The molecular glue space has attracted several Big Pharma players over the past few years, including Novo Nordisk, Pfizer and ...

Tennant Company (TNC) reported better-than-anticipated fourth-quarter 2024 results, beating analysts’ expectations.

Driven by innovative offerings and partnerships, Twilio (TWLO) has successfully established a robust footprint in the booming ...

The severity of a patient’s chronic spontaneous urticaria impacted several outcomes, including quality of life and treatment ...

The Orphan Drugs Market is experiencing significant growth due to increasing investment in rare disease research, regulatory incentives, and advancements in biotechnology. Orphan drugs are specialized ...

Adverse physical functions were indicative of reduced survival and increased risk of immune effector cell–associated neurotoxicity syndrome (ICANS) in patients with non-Hodgkin lymphoma (NHL) ...

Women's Health Therapeutics Market Rising Awareness and Government Initiatives Drive Growth AUSTIN, TX, UNITED STATES, February 28, 202 ...

Type 1 Diabetes Market Rising Prevalence and Technological Advancements Drive Market Growth AUSTIN, TX, UNITED STATES, February 28, 202 ...

Rare Disease Day, an annual gathering hosted by the FDA and National Institutes of Health, was postponed. Medicare spending on 10 diabetes drugs, including popular GLP-1s, more than quadrupled over a ...

The global seasonal affective disorder therapeutics market is set for steady growth, with revenue projected to reach USD ...